Follow-up in patients with differentiated thyroid carcinoma with positive 18f-fluoro-2-deoxy-d-glucose-positron emission tomography results, elevated thyroglobulin levels, and negative high-dose 131I posttreatment whole body scans [2]

Journal of Clinical Endocrinology and Metabolism

Volumn 85, Issue 5, 2000, Pages 2082-2083

  Van Tol, K M ^a,b   Jager, P L ^a   Dullaart, R P F ^a   Links, T P ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IODINE 131; THYROGLOBULIN;

ADULT; AGED; DIAGNOSTIC IMAGING; FEMALE; HUMAN; LETTER; MALE; METASTASIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; THYROGLOBULIN BLOOD LEVEL; THYROID CARCINOMA; WHOLE BODY SCINTISCANNING;

EID: 0034454423     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jcem.85.5.6524-2     Document Type: Letter

References (6)

1. 18F]-2- fluoro-2-deoxy-Dglucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic 131I whole body scans and elevated serum thyroglobulin levels
2. Fluorine-18 fluorodeoxyglucose positron emission tomography in the follow-up of differentiated thyroid cancer
3. Fluorine-18 fluorodeoxyglucose positron emission tomography and iodine B131 whole body scintigraphy in the follow-up of differentiated thyroid cancer
4. 131I whole-body scan
5. Therapeutic doses of iodine-131 reveal undiagnosed metastases in thyroid cancer patients with detectable serum thyroglobulin levels
6. Therapeutic controversy: The use of radioactive iodine in patients with papillary and follicular thyroid cancer